Chemoprevention or mastectomy for women at high risk of developing breast cancer

Maturitas

Volumn 82, Issue 3, 2015, Pages 271-273

  Sismondi, Piero ^a   D'Alonzo, Marta ^a   Pecchio, Silvia ^a   Bounous, Valentina Elisabetta ^a   Robba, Elisabetta ^a   Biglia, Nicoletta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer risk assessment; Chemoprevention; High risk breast cancer women; Risk reduction mastectomy; Risk reduction strategies

Indexed keywords

RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CHEMOPROPHYLAXIS; FEMALE; HUMAN; MASTECTOMY; MATHEMATICAL MODEL; POSTMENOPAUSE; REVIEW; RISK REDUCTION; VENOUS THROMBOEMBOLISM; AGE; BREAST NEOPLASMS; RISK ASSESSMENT;

AGE FACTORS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; HUMANS; MASTECTOMY; RALOXIFENE HYDROCHLORIDE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84945482772     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.07.002     Document Type: Review

References (15)

1. NCCN Guidelines 1.2015, Breast Cancer Risk Reduction.
2. H. Mitchell Gail, and P. Joseph. Costantino Validating and improving models for projecting the absolute risk of breast cancer J. Natl. Cancer Inst. 93 No. 5 2001 March 7
3. Lynn C. Hartmann, and et al. Atypical hyperplasia of the breast, risk assessment and management options N. Engl. J. Med. 372 2015 January 1
4. L.C. Hartmann, D.C. Radisky, M.H. Frost, and et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study Cancer Prev. Res. (Phila) 2014
5. Jack. Cuzick, and et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data Lancet 381 2013 May 25
6. Bernard Fisher, and et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel Project P-1 study J. Natl. Cancer Inst. 97 No. 22 2005 November 16
7. Jane A. Cauley, and et al. Continued breast cancer risk reduction in postmenopausal women treated with Raloxifene: 4-year results from the MORE Trial Breast Cancer Res. Treat. 65 2 2001 125 134 January
8. S. Martino, J.A. Cauley, and E. Barrett-Connor Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of Raloxifene J. Natl. Cancer Inst. 96 2004 1751 1761
9. D. Grady, J.A. Cauley, and M.J. Geiger Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk J. Natl. Cancer Inst. 100 2008 854 886
10. V.G. Vogel, and et al. Effects of tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA June 21 2006
11. V.G. Vogel, J.P. Costantino, D.L. Wickerham, and et al. Update of the national surgical adjuvant breast and bowel project study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer Cancer Prev. Res. (Phila) 3 2010 696 706
12. P.E. Goss, J.N. Ingle, and J.E. Ales-Martinez Exemestane for breastcancer prevention in postmenopausal women N. Engl. J. Med. 364 2011 2381 2391
13. J. Cuzick, I. Sestak, J.F. Forbes, and et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Lancet 383 2014 1041 1048
14. Hartmann, and et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer N. Engl. J. Med. 1999
15. Armando E. Giuliano, Susan Boolbol, Amy Degnim, Henry Kuerer, A. Marilyn Leitch, and Monica Morrow Society of surgical oncology: position statement on prophylactic mastectomy. Approved by the society of surgical oncology executive council Ann. Surg. Oncol. 2007 10.1245/s10434-007-9447-z